187 related articles for article (PubMed ID: 11561089)
1. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
Weiner DM; Burstein ES; Nash N; Croston GE; Currier EA; Vanover KE; Harvey SC; Donohue E; Hansen HC; Andersson CM; Spalding TA; Gibson DF; Krebs-Thomson K; Powell SB; Geyer MA; Hacksell U; Brann MR
J Pharmacol Exp Ther; 2001 Oct; 299(1):268-76. PubMed ID: 11561089
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
5. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
Herrick-Davis K; Grinde E; Teitler M
J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
[TBL] [Abstract][Full Text] [Related]
6. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
8. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
[TBL] [Abstract][Full Text] [Related]
9. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
Rauser L; Savage JE; Meltzer HY; Roth BL
J Pharmacol Exp Ther; 2001 Oct; 299(1):83-9. PubMed ID: 11561066
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C
J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656
[TBL] [Abstract][Full Text] [Related]
11. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
Egan CT; Herrick-Davis K; Teitler M
J Pharmacol Exp Ther; 1998 Jul; 286(1):85-90. PubMed ID: 9655845
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
[TBL] [Abstract][Full Text] [Related]
13. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
14. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
de Boer SF; Koolhaas JM
Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
[TBL] [Abstract][Full Text] [Related]
15. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.
Al-Shamma HA; Anderson C; Chuang E; Luthringer R; Grottick AJ; Hauser E; Morgan M; Shanahan W; Teegarden BR; Thomsen WJ; Behan D
J Pharmacol Exp Ther; 2010 Jan; 332(1):281-90. PubMed ID: 19841476
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies.
Davies MA; Setola V; Strachan RT; Sheffler DJ; Salay E; Hufeisen SJ; Roth BL
Pharmacogenomics J; 2006; 6(1):42-51. PubMed ID: 16314884
[TBL] [Abstract][Full Text] [Related]
17. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
[TBL] [Abstract][Full Text] [Related]
20. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
